


---

|                          |   |
|--------------------------|---|
| <b>Product Name</b>      | : AM095   |
| <b>Cat. No.</b>          | : PC-49650  |
| <b>CAS No.</b>           | : 1345614-59-6  |
| <b>Molecular Formula</b> | : C <sub>27</sub> H <sub>23</sub> N <sub>2</sub> NaO <sub>5</sub> |
| <b>Molecular Weight</b>  | : 478.48  |
| <b>Target</b>            | : Lysophospholipid Receptor                                       |
| <b>Solubility</b>        | : 10 mM in DMSO   |



## Biological Activity

AM095 (AM-095) is a potent, selective and orally active lysophosphatidic acid type 1 receptor (**LPA1**) antagonist with IC<sub>50</sub> of 0.98 and 0.73 μM for hLPA1 and mLPA1 in GTP S binding assays, respectively, with no LPA1 agonism.

AM095 inhibited LPA-driven chemotaxis of CHO cells overexpressing mouse LPA1 (IC<sub>50</sub>=778 nM) and human A2058 melanoma cells (IC<sub>50</sub>=233 nM) in function assays.

AM095 inhibited LPA1-driven chemotaxis of both human A2058 melanoma cells (IC<sub>50</sub> =0.23 μM) and mouse LPA1/CHO cells (IC<sub>50</sub>=0.78 μM)。

AM095 dose-dependently reduced LPA-stimulated histamine release, attenuated bleomycin-induced increases in collagen, protein, and inflammatory cell infiltration in bronchialveolar lavage fluid in vivo.

AM095 decreased kidney fibrosis in a mouse unilateral ureteral obstruction model.

## References

Swaney JS, et al. *J Pharmacol Exp Ther*. 2011 Mar;336(3):693-700.

---

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com

---